Comparing SG&A Expenses: Perrigo Company plc vs BioCryst Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and BioCryst Pharmaceuticals, Inc. from 2014 to 2023.

Perrigo Company plc: A Steady Climb

Perrigo's SG&A expenses have shown a consistent upward trend, peaking at approximately $1.27 billion in 2023. This represents a 47% increase from 2014, reflecting the company's strategic investments in marketing and administration to maintain its competitive edge.

BioCryst Pharmaceuticals, Inc.: Rapid Growth

In contrast, BioCryst's SG&A expenses surged by an astounding 2,768% over the same period, reaching around $214 million in 2023. This dramatic rise underscores BioCryst's aggressive expansion and increased operational activities.

Insights and Implications

The stark contrast in SG&A growth rates highlights differing strategic priorities. While Perrigo focuses on steady growth, BioCryst's rapid increase suggests a more aggressive market approach.